[1] Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing 2019;48:16–31. https:///10.1093/ageing/afy169.
[2] Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obesity Facts 2022;15:321–35. https:///10.1159/000521241.
[3] Kim G, Kang SH, Kim MY, Baik SK. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS ONE 2017;12:1–16. https:///10.1371/journal.pone.0186990.
[4] Zeng X, Shi ZW, Yu JJ, Wang LF, Luo YY, Jin SM, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. Journal of Cachexia, Sarcopenia and Muscle 2021;12:1948–58. https:///10.1002/jcsm.12797.
[5] Maryam E, Aldo J M-L. Sarcopenia and Frailty in the Prognosis of Patients on the Liver Transplant Waiting List. Liver Transpl 2019;25:7–9. https:///10.1002/lt.25386.
[6] Sinclair M, Gow PJ, Grossmann M, Angus PW. sarcopenia in cirrhosis – aetiology , implications and potential therapeutic interventions. Alimentary Pharmacology and Therapeutics Review 2016;43:765–77. https:///10.1111/apt.13549.
[7] Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74:1611–44. https:///10.1002/hep.32049.
[8] Carey E, Lai JC, Wang CW, Dasarathy S, Lobach I, Montano-Loza AJ, et al. A Multicenter Study to Define Sarcopenia in Patients With End- Stage Liver Disease. Liver Transpl 2017;23:625–33. https:///10.1002/lt.24750.A.
[9] EASL. EASL Clinical Practice Guidelines on nutrition. J Hepatol 2019;70:139–48. https:///10.1016/j.jhep.2018.06.024.EASL.
[10] Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. Journal of Hepatology 2021;75:S147–62. https:///10.1016/j.jhep.2021.01.025.
[11] Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. Journal of Gastroenterology 2019;54:845–59. https:///10.1007/s00535-019-01605-6.
[12] Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol 1995;103:63–74.
[13] Kaye GL, Kruszynska YT, Harry DS, Heslop K, Johnston DG, McIntyre N. Lipid metabolism and insulin resistance in cirrhosis. Journal of Hepatology 1994;20:782–91. https:///10.1016/S0168-8278(05)80150-3.
[14] Katayama K. Zinc and protein metabolism in chronic liver diseases. vol. 74. The Author. Published by Elsevier Inc; 2020. https:///10.1016/j.nutres.2019.11.009.
[15] Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection : Host – Virus Interaction. Cell 2019;376:1–27.
[16] Bessone F, Valeria M, Marcelo R. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cellular and Molecular Life Sciences 2019;76:99–128. https:///10.1007/s00018-018-2947-0.
[17] Pan L, Xie W, Fu X, Lu W, Jin H, Lai J, et al. Inflammation and sarcopenia : A focus on circulating inflammatory cytokines. Experimental Gerontology 2021;154:111544. https:///10.1016/j.exger.2021.111544.
[18] Shin MJ, Jeon YK, Kim IJ. Testosterone and Sarcopenia. World J Mens Health 2018;36:192–8.
[19] Baumgartner RN, Koehler KM, Romero L, Garry PJ. Serum albumin is associated with skeletal muscle in elderly men and women. American Journal of Clinical Nutrition 1996;64:552–8. https:///10.1093/ajcn/64.4.552.
[20] Van Atteveld VA, Van Ancum JM, Reijnierse EM, Trappenburg MC, Meskers CGM, Maier AB. Erythrocyte sedimentation rate and albumin as markers of inflammation are associated with measures of sarcopenia: A cross-sectional study. BMC Geriatrics 2019;19:1–8. https:///10.1186/s12877-019-1253-5.
[21] Alexopoulos T, Vasilieva L, Kontogianni MD, Tenta R, Georgiou A, Stroumpouli E, et al. Myostatin in combination with creatine phosphokinase or albumin may differentiate patients with cirrhosis and sarcopenia. American Journal of Physiology Gastrointestinal and Liver Physiology 2021;321:G543–51. https:///10.1152/ajpgi.00184.2021.
[22] D CLR, D TBBM, Ph D, D AMM, Ph D, D SWM, et al. Assessment of muscle mass depletion in chronic liver disease : Dual-energy x-ray absorptiometry compared with computed tomography. Nutrition 2019;61:93–8. https:///10.1016/j.nut.2018.10.031.
[23] Tandon P, Ismond KP, Riess K, Duarte-rojo A, Al-judaibi B, Dunn MA, et al. Exercise in cirrhosis : Translating evidence and experience to practice. Journal of Hepatology 2018;69:1164–77. https:///10.1016/j.jhep.2018.06.017.
[24] Sinclair M, Grossmann M, Gow PJ, Angus PW. Testosterone in men with advanced liver disease : Abnormalities and implications. J Gastroenterol Hepatol 2015;30:244–51. https:///10.1111/jgh.12695.
[25] Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Effects of Oral Branched-Chain Amino Acid Granules on Event-Free Survival in Patients With Liver Cirrhosis. Clin Gastroenterol Hepatol 2005;3:705–13.
[26] Kitajima Y, Takahashi H, Akiyama T, Murayama K. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia , prevents sarcopenia , and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis. Journal of Gastroenterology 2017. https:///10.1007/s00535-017-1370-x.
[27] Hanai T, Shiraki M, Imai K, Suetugu A, Takai K, Shimizu M. Usefulness of carnitine supplementation for the complications of liver cirrhosis. Nutrients 2020;12:1–11. https:///10.3390/nu12071915.
[28] Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, et al. Oral acetyl- L -carnitine therapy reduces fatigue in overt hepatic encephalopathy : a randomized , double-blind , placebo-controlled study. Am J Clin Nutr 2011;93:799–808. https:///10.3945/ajcn.110.007393.Hepatic.
[29] Communications H, Tanaka J, Chayama K, Hiramatsu A, Aikata H, Uchikawa S, et al. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients. Hepatology Communications 2019;3:348–55. https:///10.1002/hep4.1309.
[30] Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. Review The search for disease-modifying agents in decompensated cirrhosis : From drug repurposing to drug discovery. Journal of Hepatology 2021;75:S118–34. https:///10.1016/j.jhep.2021.01.024.
[31] Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. The Lancet 2018;391:2417–29. https:///10.1016/S0140-6736(18)30840-7.
[32] Kumar A, Davuluri G, Tenhave G, Prayson R, Clinic C, Clinic C, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatol 2017;65:2045–58. https:///10.1002/hep.29107.Ammonia.
[33] Kim RG, Loomba R, Prokop LJ, Singh S. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017;15:1521–30. https:///10.1016/j.cgh.2017.04.039.Statin.
[34] Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clinical and Molecular Hepatology 2021;27:425–36. https:///10.3350/cmh.2020.0234.